Silco Pharmaceuticals Limited

DSE:SILCOPHL Stock Report

Market Cap: ৳1.7b

Silco Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Silco Pharmaceuticals's earnings have been declining at an average annual rate of -21.5%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 17.5% per year. Silco Pharmaceuticals's return on equity is 1.8%, and it has net margins of 10.1%.

Key information

-21.5%

Earnings growth rate

-26.5%

EPS growth rate

Pharmaceuticals Industry Growth11.0%
Revenue growth rate-17.5%
Return on equity1.8%
Net Margin10.1%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Silco Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DSE:SILCOPHL Revenue, expenses and earnings (BDT Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2442243610
31 Dec 2343648650
30 Sep 2343750660
30 Jun 2346569700
31 Mar 2341868700
31 Dec 2247482740
30 Sep 2250479750
30 Jun 2255984810
31 Mar 2255288730
31 Dec 2156187760
30 Sep 2154686750
30 Jun 2160185800
31 Mar 21681841000
31 Dec 20691761030
30 Sep 20740881130
30 Jun 20734831100
31 Mar 208141631290
31 Dec 198561671330
30 Sep 199301681410
30 Jun 199191621380
31 Mar 199201061320
31 Dec 189241051340
30 Sep 189101041330
30 Jun 189181051320
30 Jun 179071031300
30 Jun 168861191300
31 Dec 158511171260
31 Dec 14810601200
31 Dec 139981411240

Quality Earnings: SILCOPHL has a large one-off gain of BDT18.6M impacting its last 12 months of financial results to 31st March, 2024.

Growing Profit Margin: SILCOPHL's current net profit margins (10.1%) are lower than last year (16.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SILCOPHL's earnings have declined by 21.5% per year over the past 5 years.

Accelerating Growth: SILCOPHL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SILCOPHL had negative earnings growth (-37.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.3%).

Return on Equity

High ROE: SILCOPHL's Return on Equity (1.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 04:15
End of Day Share Price 2024/12/24 00:00
Earnings2024/03/31
Annual Earnings2023/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Silco Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution